Recent approvals by the US Federal Drug Administration (FDA) have led to the availability in America of two new eye drop therapies for Glaucoma. Rhopressa and Vyzulta both reduce intraocular pressure in patients suffering open-angle glaucoma or ocular hypertension.

Both drugs are part of a new class of treatments which target the trabecular network - the main drain through which fluid leaves the eye. One area for on-going research is how the new drugs work in combination with other prostaglandins, which remains unclear.

Although the drugs are not suitable for all glaucoma sufferers, the approvals will be welcome news for many who would prefer non-surgical options.

Sources:

1. Reuters:
   Aerie's glaucoma drug effectively lowers eye pressure: FDA review.

2. Ophthalmology Times:
   New glaucoma therapy offers first drug option in years.

3. European Pharmaceutical Review:
   FDA approves Vyzulta for open-angle glaucoma and ocular hypertension.